66
Participants
Start Date
November 13, 2025
Primary Completion Date
May 13, 2028
Study Completion Date
May 13, 2029
Rezpegaldesleukin
Rezpegaldesleukin will be dosed at 12 μg/kg for subcutaneous injection. Rezpegaldesleukin will be provided as a 1.5 mg/mL sterile solution in a vial for injection preparation. Study agent injections will be administered in the abdomen, back of the upper arm or the upper thigh of the participant.
Placebo
Sterile saline for injection. Placebo will be administered in the same volume and as the active comparator to maintain treatment masking.
Vanderbilt University, Nashville
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH